To support the conclusion of the metabolic network analysis, we have experimentally evaluated the serum levels of TP53 in HCC and T2D patients, showing how they are correlated with the CXCL12 levels and thus confirming that TP53 can suppress the production of this chemokine as already reported in cultured fibroblasts of both human and mouse origin [54]. Here, CXCL12 is linked to type 2 diabetes mellitus.